

POSTER PRESENTATION

Open Access

# The CD40 agonistic monoclonal antibody APX005M has potent immune stimulatory capabilities

Pia Bjorck, Erin Filbert, Yongke Zhang, Xiaodong Yang, Ovid Trifan\*

From 30th Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2015) National Harbor, MD, USA. 4-8 November 2015

The co-stimulatory receptor CD40 is a member of the tumor necrosis factor receptor (TNFR) superfamily and plays an important role in the control and regulation of immune activation, especially in crosstalk between T cells and antigen presenting cells (APCs). The natural ligand for CD40 (CD40L, CD154) is expressed on activated T cells and provides a major component of T cell “help” for the immune response. Agonistic CD40 antibodies can substitute for the function of CD154 on T cells to boost immunity by stimulating antigen presentation and co-stimulation to T cells and have been shown to be potent boosters of anti-tumor immune responses. Anti-CD40 can directly inhibit tumor growth in CD40 expressing tumor cells.

APX005M is a humanized IgG1 monoclonal antibody that binds CD40 with high affinity and blocks the binding of CD40 to CD40L. APX005M activates dendritic cells, B cells and monocytes, and promotes antigen-specific T cell responses. APX005M demonstrates potent anti-tumor activity via ADCC and induction of apoptosis in CD40 expressing tumor cells. In comparison with other CD40 agonistic antibodies such as CP-870, 893 and SGN-40 analogs, APX005M has more potent CD40 agonistic effects and antibody effector function.

Published: 4 November 2015

doi:10.1186/2051-1426-3-S2-P198

**Cite this article as:** Bjorck et al.: The CD40 agonistic monoclonal antibody APX005M has potent immune stimulatory capabilities. *Journal for ImmunoTherapy of Cancer* 2015 **3**(Suppl 2):P198.

Submit your next manuscript to BioMed Central and take full advantage of:

- Convenient online submission
- Thorough peer review
- No space constraints or color figure charges
- Immediate publication on acceptance
- Inclusion in PubMed, CAS, Scopus and Google Scholar
- Research which is freely available for redistribution

Submit your manuscript at  
[www.biomedcentral.com/submit](http://www.biomedcentral.com/submit)



Apexigen, Inc., San Carlos, CA, USA



© 2015 Bjorck et al. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<http://creativecommons.org/licenses/by/4.0>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver (<http://creativecommons.org/publicdomain/zero/1.0/>) applies to the data made available in this article, unless otherwise stated.